SCHEDULE 13G Filed 2026-11-06 Event — SEC 0001123292-26-001496 →

GILEAD SCIENCES, INC. → Aspen Neuroscience, Inc. ASPE

Stake: — Shares: — Class: Common Stock, par value $0.0001 per share

Composite Decision Signal · AVOID (DILUTION / EXIT TRAP) Conviction Score: 25/100 · Filer 90d Win Rate: 0% · Hist. 90d Edge: +0.0%

Disqualifiers: PIPE_OR_FINANCING_ARTIFACT: Uniform >=$10M structured financing block

Filer track record (3 filings): 0% 90d win rate, +0.0% 90d edge
2 independent officer/director Code-P buyers ($30,000,000 in ±30d)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

27 transactions

6 buys · 0 sales · 0 awards/exercises

Issuer Cluster

4 13D/G filings on this issuer

3 other filings besides this one

Filer Track Record

10 filings by this filer

9 other filings in the data moat

Short Interest

—

Not in latest FINRA snapshot

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-11-02	ARCH Venture Fund X, L.P.	10%+ owner	Buy	66,666	$15.00	$1000K
2026-11-02	ARCH Venture Fund X, L.P.	10%+ owner	C	187,182	—	—
2026-11-02	ARCH Venture Fund X, L.P.	10%+ owner	C	298,258	—	—
2026-11-02	ARCH Venture Fund X, L.P.	10%+ owner	C	286,304	—	—
2026-11-02	ARCH Venture Fund X, L.P.	10%+ owner	C	295,490	—	—
2026-11-02	ARCH Venture Fund X, L.P.	10%+ owner	C	259,948	—	—
2026-11-02	ARCH Venture Fund X, L.P.	10%+ owner	Buy	66,667	$15.00	$1.00M
2026-11-02	ARCH Venture Fund X, L.P.	10%+ owner	C	214,355	—	—
2026-11-02	ARCH Venture Fund X, L.P.	10%+ owner	Buy	1,200,000	$15.00	$18.00M
2026-11-02	ARCH Venture Partners XIV, L.P.	10%+ owner	Buy	1,200,000	$15.00	$18.00M
2026-11-02	Spaventa Andrew	director	C	70,194	—	—
2026-11-02	Spaventa Andrew	director	C	180,221	—	—
2026-11-02	Hasnain Faheem	director, officer	C	14,913	—	—
2026-11-02	Hasnain Faheem	director, officer	C	14,316	—	—
2026-11-02	Hasnain Faheem	director, officer	C	7,120	—	—
2026-11-02	Thompson Peter A.	director, 10%+ owner	C	196,541	—	—
2026-11-02	Thompson Peter A.	director, 10%+ owner	C	642,745	—	—
2026-11-02	Thompson Peter A.	director, 10%+ owner	C	616,984	—	—
2026-11-02	Thompson Peter A.	director, 10%+ owner	C	625,743	—	—
2026-11-02	Thompson Peter A.	director, 10%+ owner	C	507,119	—	—
2026-11-02	Thompson Peter A.	director, 10%+ owner	Buy	1,000,000	$15.00	$15.00M
2026-11-02	ORBIMED ADVISORS LLC	director, 10%+ owner	C	196,541	—	—
2026-11-02	ORBIMED ADVISORS LLC	director, 10%+ owner	C	642,745	—	—
2026-11-02	ORBIMED ADVISORS LLC	director, 10%+ owner	C	616,984	—	—
2026-11-02	ORBIMED ADVISORS LLC	director, 10%+ owner	C	625,743	—	—

Showing 25 of 27

Other 13D/G Filings on Aspen Neuroscience, Inc.

Filed	Form	Filer	Stake	Shares
2026-11-06	SCHEDULE 13D	ORBIMED ADVISORS LLC	12.30%	3,589,132	view →
2026-11-06	SCHEDULE 13G	FMR LLC	—	—	view →
2026-11-03	SCHEDULE 13G	Qatar Investment Authority	—	—	view →

Other Filings by GILEAD SCIENCES, INC.

Filed	Form	Issuer	Stake	Shares
2026-08-07	SCHEDULE 13D/A	Arcus Biosciences, Inc.	24.70%	31,424,760	view →
2026-05-27	SCHEDULE 13D/A	ASSEMBLY BIOSCIENCES, INC. ASMB	25.10%	4,977,089	view →
2026-04-28	SCHEDULE 13D/A	Arcellx, Inc.	—	100	view →
2025-02-20	SCHEDULE	Arcus Biosciences, Inc. RCUS	35.00%	39,691,649	view →
2025-01-10	SCHEDULE	GALAPAGOS NV GLPGF	29.90%	20,981,010	view →
2024-06-20	SC	ASSEMBLY BIOSCIENCES, INC. ASMB	—	—	view →
2023-07-06	SC	Arcus Biosciences, Inc. RCUS	—	—	view →
2021-02-02	SC	Arcus Biosciences, Inc. RCUS	—	—	view →
2019-08-29	SC	GALAPAGOS NV GLPGF	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →